Probiotics in the Management of Functional Bowel Disorders. Promise Fulfilled?

Gastroenterology Clinics of North America

Volumn 41, Issue 4, 2012, Pages 805-819

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bloating; Constipation; Functional bowel disorders; Irritable bowel syndrome; Microbiota; Probiotics

Indexed keywords

LACTULOSE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; CONSTIPATION; DAILY LIFE ACTIVITY; ESCHERICHIA COLI; HOST RESISTANCE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; MEDICAL RESEARCH; NONHUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

CHRONIC DISEASE; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; METAGENOME; PROBIOTICS;

EID: 84867946230     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.08.005     Document Type: Review

References (140)

1. Quigley E.M., Abdel-Hamid H., Barbara G., et al. A global perspective on irritable bowel syndrome: a consensus statement of the world gastroenterology organisation summit task force on irritable bowel syndrome. J Clin Gastroenterol 2012, 46:356-366.
2. Brandt L.J., Locke G.R., Olden K., et al. An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(Suppl):S1-S26.
3. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
4. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
5. Thompson W.G., Heaton K.W., Smyth G.T., et al. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000, 46:78-82.
6. Hungin A.P., Whorwell P.J., Tack J., et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003, 17:643-650.
7. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., American College of Gastroenterology Task Force on Irritable Bowel Syndrome, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35.
8. Ruepert L., Quartero A.O., de Wit N.J., et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011, (8). CD003460.
9. Quigley E.M. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol 2003, 38(Suppl 237):1-8.
10. McKee D.P., Quigley E.M. Intestinal motility and the irritable bowel syndrome - Is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci 1993, 38:1761-1772.
11. McKee D.P., Quigley E.M. Intestinal motility and the irritable bowel syndrome-is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach and gall bladder. Dig Dis Sci 1993, 38:1773-1782.
12. Zhou Q., Verne G.N. New insights into visceral hypersensitivity-clinical implications in IBS. Nat Rev Gastroenterol Hepatol 2011, 8:349-355.
13. Quigley E.M. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon?. Gastroenterol Clin North Am 2005, 34:221-233.
14. Spiller R., Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979-1988.
15. Thabane M., Marshall J.K. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009, 15:3591-3596.
16. Marshall J.K., Thabane M., Garg A.X., et al. Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010, 59:605-611.
17. Villani A.C., Lemire M., Thabane M., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010, 138:1502-1513.
18. Braak B., Klooker T.K., Wouters M.M., et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?. Am J Gastroenterol 2012, 107:715-726.
19. Martínez C., Vicario M., Ramos L., et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012, 107:736-746.
20. Chang L., Adeyemo M., Karagiannides I., et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012, 107:262-272.
21. Collins S.M. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002, 122:2078-2080.
22. Ohman L., Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010, 7:163-173.
23. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693-702.
24. Barbara G., Wang B., Stanghellini V., et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007, 132:26-37.
25. Cenac N., Andrews C.N., Holzhausen M., et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007, 117:636-647.
26. Guilarte M., Santos J., de Torres I., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56:203-209.
27. Quigley E.M. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am 2011, 40:207-222.
28. O'Mahony L., McCarthy J., Kelly P., et al. A Randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and Bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
29. Liebregts T., Adam B., Bredack C., et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913-920.
30. Dinan T.G., Quigley E.M., Ahmed S.M., et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology 2006, 130:304-311.
31. Scully P., McKernan D.P., Keohane J., et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010, 105:2235-2243.
32. O'Malley D., Quigley E.M., Dinan T.G., et al. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?. Brain Behav Immun 2011, 25:1333-1341.
33. McKernan D.P., Gaszner G., Quigley E.M., et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011, 33:1045-1052.
34. Brint E.K., MacSharry J., Fanning A., et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011, 106:329-336.
35. Ghoshal U.C., Shukla R., Ghoshal U., et al. The gut microbiota and irritable bowel syndrome: friend or foe?. Int J Inflam 2012, 2012:151085.
36. Pimentel M., Chow E.J., Lin H.C. Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
37. Pimentel M., Chow E., Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
38. Posserud I., Stotzer P.O., Bjornsson E., et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2006, 56:802-808.
39. Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut 2008, 57:1315-1321.
40. Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am J Gastroenterol 2008, 103:964-965.
41. Bratten J.R., Spanier J., Jones M.P. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008, 103:958-963.
42. Ford A.C., Spiegel B.M., Talley N.J., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009, 7(12):1279-1286.
43. Spiegel B.M. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011, 9:461-469.
44. Malinen E., Rinttilä T., Kajander K., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100:373-382.
45. Codling C., O'Mahony L., Shanahan F., et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010, 55:392-397.
46. Rajilić-Stojanović M., Biagi E., Heilig H.G., et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011, 141:1792-1801.
47. Saulnier D.M., Riehle K., Mistretta T.A., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011, 141:1782-1791.
48. Shanahan F. Therapeutic manipulation in gut flora. Science 2000, 289:1311-1312.
49. Collins S.M. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996, 111:1683-1699.
50. Gorbach S.L. Probiotics in the third millennium. Dig Liver Dis 2002, 34(Suppl 2):S2-S7.
51. Preidis G.A., Hill C., Guerrant R.L., et al. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 2011, 140:8-14.
52. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
53. Keohane J., O'Mahony C., O'Mahony L., et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol 2010, 105:1788-1794.
54. O'Leary C., Wieneke P., Buckley S., et al. Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol 2002, 97:1463-1467.
55. Clarke G., Cryan J.F., Dinan T.G., et al. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 2012, 35:403-413.
56. Quigley E.M. Microflora modulation of motility. J Neurogastroenterol Motil 2011, 17:140-147.
57. Quigley E.M. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol 2011, 25:119-126.
58. Theoharides T.C., Asadi S., Chen J., et al. Editorial: irritable bowel syndrome and the elusive mast cells. Am J Gastroenterol 2012, 107:727-729.
59. O'Mahony L., Feeney M., O'Halloran S., et al. Probiotic impact on microbial flora, inflammation, and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001, 15:1219-1225.
60. McCarthy J., O'Mahony L., O'Callaghan L., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52:975-980.
61. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
62. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
63. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
64. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
65. Johnson A.C., Greenwood-Van Meerveld B., McRorie J. Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 2011, 56:3179-3186.
66. McKernan D.P., Fitzgerald P., Dinan T.G., et al. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 2010, 22:1029-1035.
67. Verdu E.F., Bercik P., Bergonzelli G.E., et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004, 127:826-837.
68. Jijon H., Backer J., Diaz H., et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004, 126:1358-1373.
69. Ait-Belgnaoui A., Han W., Lamine F., et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006, 55:1090-1094.
70. Eutamene H., Lamine F., Chabo C., et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007, 137:1901-1907.
71. Dai C., Guandalini S., Zhao D.H., et al. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem 2012, 362:43-53.
72. Konieczna P., Groeger D., Ziegler M., et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012, 61:354-366.
73. Konieczna P., Akdis C.A., Quigley E.M., et al. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012, 3(3):261-266.
74. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:326-333.
75. Jiang T., Savaiano D.A. Modification of colonic fermentation by bifidobacteria and pH in vitro: impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 1997, 42:2370-2377.
76. Begley M., Hill C., Gahan C.G. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006, 72:1729-1738.
77. Ouwehand A.C., Lagstrom H., Suomalainen T., et al. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002, 46:159-162.
78. Ong D.K., Mitchell S.B., Barrett J.S., et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010, 25:1366-1373.
79. Biesiekierski J.R., Newnham E.D., Irving P.M., et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011, 106:508-514.
80. Piche T., des Varannes S.B., Sacher-Huvelin S., et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 2003, 124:894-902.
81. Ropert A., Cherbut C., Roze C., et al. Colonic fermentation and proximal gastric tone in humans. Gastroenterology 1996, 111:289-296.
82. Camilleri M., Di Lorenzo C. Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr 2012, 54:446-453.
83. Cryan J.F., O'Mahony S.M. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011, 23:187-192.
84. Grenham S., Clarke G., Cryan J.F., et al. Brain-gut-microbe communication in health and disease. Front Physiol 2011, 2:94.
85. Bravo J.A., Forsythe P., Chew M.V., et al. Ingestion of lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011, 108:16050-16055.
86. Bercik P., Park A.J., Sinclair D., et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 2011, 23:1132-1139.
87. Bercik P., Denou E., Collins J., et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011, 141:599-609.
88. Heijtz R.D., Wang S., Anuar F., et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011, 108:3047-3052.
89. Zoppi G., Cinquetti M., Luciano A., et al. The intestinal ecosystem in chronic functional constipation. Acta Paediatr 1998, 87:836-841.
90. Khalif I.L., Konovitch E.A., Maximova I.D., et al. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005, 37:838-849.
91. Celik A.F., Tomlin J., Read N.W. The effect of oral vancomycin on chronic idiopathic constipation. Aliment Pharmacol Ther 1995, 9:63-68.
92. Hwang L., Low K., Khoshini R., et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Dig Dis Sci 2010, 55:398-403.
93. Sahakian A.B., Jee S.R., Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci 2010, 55:2135-2143.
94. Attaluri A., Jackson M., Valestin J., et al. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 2010, 105:1407-1411.
95. Lesniewska V., Rowland I., Laerke H.N., et al. Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo. Exp Physiol 2006, 91:229-237.
96. Matsumoto M., Ishige A., Yazawa Y., et al. Promotion of intestinal peristalsis by Bifidobacterium spp. Capable of hydrolysing sennosides in mice. PLoS One 2012, 7:e31700.
97. Marteau P., Cuillerier E., Meance S., et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002, 16:587-593.
98. Bouvier M., Meance S., Bouley C., et al. Effects of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Biosci Microflora 2001, 20:43-48.
99. Meance S., Cayuela C., Turchet P., et al. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001, 13:217-222.
100. Agrawal A., Houghton L.A., Morris J., et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009, 29:104-114.
101. Hamilton-Miller J.M. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001, 13:212-216.
102. Nobaek S., Johansson M.L., Molin G., et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231-1238.
103. O'Sullivan M.A., O'Morain C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:302-304.
104. Brigidi P., Vitali B., Swennen E., et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001, 152:735-741.
105. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143-1147.
106. Sen S., Mullan M.M., Parker T.J., et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2620.
107. Bazzocchi G., Gionchetti P., Almerigi P.F., et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002, 34(Suppl 2):s48-s53.
108. Kim H.J., Camilleri M., McKinzie S., et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895-904.
109. Ringel-Kulka T., Palsson O.S., Maier D., et al. Probiotic bacteria lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011, 45:518-525.
110. Horvath A., Dziechciarz P., Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011, 33:1302-1310.
111. Ki Cha B., Mun Jung S., Hwan Choi C., et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012, 46:220-227.
112. Choi C.H., Jo S.Y., Park H.J., et al. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011, 45:679-683.
113. Nikfar S., Rahimi R., Rahimi F., et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008, 51:1775-1780.
114. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008, 14:2650-2661.
115. Hoveyda N., Heneghan C., Mahtani K.R., et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009, 9:15.
116. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008, 59(3):325-332.
117. Brenner D.M., Moeller M.J., Chey W.D., et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009, 104(4):1033-1049. [quiz: 1050].
118. Kabir M.A., Ishaque S.M., Ali M.S., et al. Role of saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011, 20:397-401.
119. Søndergaard B., Olsson J., Ohlson K., et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011, 46:663-672.
120. Guyonnet D., Chassany O., Ducrotte P., et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007, 26:475-486.
121. Guglielmetti S., Mora D., Gschwender M., et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011, 33:1123-1132.
122. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22:387-394.
123. Kajander K., Myllyluoma E., Rajilić-Stojanović M., et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008, 27:48-57.
124. Koebnick C., Wagner I., Leitzmann P., et al. Probiotic beverage containing Lactobacillus casei shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003, 17:655-659.
125. Yang Y.X., He M., Hu G., et al. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 2008, 14:6237-6243.
126. Banaszkiewicz A., Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005, 146:364-369.
127. Coccorullo P., Strisciuglio C., Martinelli M., et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 2010, 157:598-602.
128. Amenta M., Cascio M.T., Di Fiore P., et al. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006, 77:157-162.
129. De Paula J.A., Carmuega E., Weill R. Effect of the ingestion of a symbiotic yogurt on the bowel habits of women with functional constipation. Acta Gastroenterol Latinoam 2008, 38:16-25.
130. Bekkali N.L., Bongers M.E., Van den Berg M.M., et al. The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. Nutr J 2007, 6:17.
131. Bu L.N., Chang M.H., Ni Y.H., et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 2007, 49:485-490.
132. Borody T.J., Warren E.F., Leis S.M., et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004, 38:475-483.
133. Pitkala K.H., Strandberg T.E., Finne Soveri U.H., et al. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007, 11:305-311.
134. An H.M., Baek E.H., Jang S., et al. Efficacy of lactic acid bacteria (LAB) supplement in management of constipation among nursing home residents. Nutr J 2010, 9:5.
135. Chmielewska A., Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol 2010, 16:69-75.
136. Guerra P.V., Lima L.N., Souza T.C., et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol 2011, 17:3916-3921.
137. Tabbers M.M., Chmielewska A., Roseboom M.G., et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 2011, 127:e1392-e1399.
138. Del Piano M., Carmagnola S., Anderloni A., et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study. J Clin Gastroenterol 2010, 44(Suppl 1):S30-S34.
139. Riezzo G., Orlando A., D'Attoma B., et al. Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation-a double-blind, controlled, crossover study. Aliment Pharmacol Ther 2012, 35:441-450.
140. McKenzie Y.A., Alder A., Anderson W., et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012, 25:260-274. On behalf of Gastroenterology Specialist Group of the British Dietetic Association.